August 2026 - Increased Hematopoietic Stem Cell Mobilization drug patent expiration information, FTO search

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys	PLERIXAFOR	plerixafor	SOLUTION;SUBCUTANEOUS	205182-001	Jul 24, 2023	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Eugia Pharma	PLERIXAFOR	plerixafor	SOLUTION;SUBCUTANEOUS	213672-001	Jul 24, 2023	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Amneal	PLERIXAFOR	plerixafor	SOLUTION;SUBCUTANEOUS	215334-001	Jul 24, 2023	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 23, 2026

Drugs with the physiological effect of increased hematopoietic stem cell (HSC) mobilization cluster around two MoAs: (1) CXCR4 antagonism (notably plerixafor) and (2) regimen-driven mobilization built on cytokines and chemo-based stress. From a patent and commercialization standpoint, the highest-value IP sits in specific indications (autologous transplant mobilization), dosing regimens, combination use, and manufacturing control. Patent expiry and exclusivity windows vary sharply by active ingredient and region, but the competitive trigger is consistent: when branded exclusivity ends, generics and authorized biosimilars for cytokines can shift unit economics quickly, while payer and transplant center contracts determine uptake.

Which drugs increase hematopoietic stem cell mobilization, and how do their patent estates differ?

What is the key MoA for HSC mobilization?

Primary commercial categories

CXCR4 antagonists: disrupt bone-marrow retention signaling, rapidly mobilizing CD34+ cells.
Cytokine- and chemo-based mobilization: uses growth factors (especially G-CSF) ± chemotherapy to shift stem cell kinetics.
Adjunct regimen components: include additional agents used to improve yield or reduce mobilization failure.

What is the main “basket” of products used in practice?

CXCR4 pathway

Plerixafor (in combination with G-CSF) for autologous transplant mobilization in patients who fail prior mobilization or are predicted to be poor mobilizers.

Cytokine pathway

Filgrastim (G-CSF) and pegfilgrastim derivatives for mobilization regimens (often off-label or label-scoped depending on geography).
Biosimilars and authorized generics are common once originator exclusivity ends.

Chemo-based mobilization

Regimens using chemo plus G-CSF often drive mobilization success; patent protection typically targets specific combinations, sequences, or dosing schedules rather than the cytotoxic drug itself.

What patents protect plerixafor (CXCR4) for hematopoietic stem cell mobilization?

What is plerixafor’s commercial footprint?

Plerixafor is the clearest “IP-dense” mobilization drug because it is a targeted small molecule with limited generic entry history relative to G-CSF lines.
Market uptake is driven by transplant centers’ need for predictable CD34+ yields and by payers’ prior-authorization practices tied to mobilization failure risk.

What types of patents typically protect HSC mobilization via CXCR4 antagonism?

Patent protection for plerixafor and similar CXCR4 antagonists generally concentrates in:

Compound and composition-of-matter (early-expiring but foundational)
Formulations (salt forms, lyophilized vs solution, excipients, and stability)
Methods of use: mobilization in autologous hematopoietic stem cell transplantation
Patient selection and risk stratification: “poor mobilizer” definitions that are operationalized in labels and protocols
Combination methods with G-CSF: timing and dosing sequences to maximize CD34+ collection

How many patent “buckets” matter for generic competition?

For CXCR4 antagonists, the practical generic barrier is usually not only the base compound patent but also:

Method-of-use and label-tied claims
Combination regimen claims with G-CSF
Formulation claims that constrain product design or impose design-around work

When does HSC mobilization drug exclusivity end, and what timelines govern generic or biosimilar entry?

What matters for exclusivity timelines in the US?

For small molecules like plerixafor and for biologics like G-CSF:

NDA exclusivity and patent term can extend entry beyond the earliest composition-of-matter.
Orange Book listings typically anchor risk for Paragraph IV filings and 180-day exclusivity triggers.
Payer contracting often delays “market share transfer” even after legal eligibility is achieved.

What is the typical sequence of barriers to entry?

Commercial entry ladder

Patent expiration (composition and key method/regimen patents)
Regulatory eligibility (ANDA approval requirements; generic bioequivalence)
Orange Book / patent litigation stay or final determination
Manufacturing readiness and lot-to-lot quality controls
Contracting and utilization management (prior authorization, preferred provider rules)

How do these timelines differ between CXCR4 antagonists and G-CSF biologics?

CXCR4 antagonists: fewer parallel products, so exclusivity and method-of-use patents can keep a branded share longer.
G-CSF: multiple approved competitors and biosimilars drive earlier price competition; remaining legal value centers on specific dosing/formulation and label language.

What is the Orange Book status of HSC mobilization drugs like plerixafor, filgrastim, and pegfilgrastim?

How Orange Book status typically drives challenge risk?

If Orange Book lists multiple method-of-use and formulation patents for autologous transplant mobilization, Paragraph IV challenges are more likely to trigger litigation.
If Orange Book coverage is thin or narrow, generics can launch with fewer design-around steps.

What Orange Book patterns appear across mobilization products?

CXCR4 antagonists: usually show dense method-of-use coverage.
G-CSF: often shows fewer incremental method claims for mobilization once label scope is set; price competition then depends on biosimilar interchangeability and payer formularies.

How strong is the patent estate for hematopoietic stem cell mobilization, and which claims tend to survive design-arounds?

What claim categories are strongest in litigation?

The claims most likely to remain enforceable in HSC mobilization disputes are:

Method-of-use claims that map tightly to the FDA label (e.g., “mobilize peripheral blood stem cells for autologous transplantation in patients with X”).
Combination regimen claims with specific G-CSF scheduling.
Formulation/stability claims that block straightforward generic replication.

What is weaker in practice?

Broad genus claims to CXCR4 antagonism or general “mobilization” language can be vulnerable if the prior art is strong or if the claim is interpreted narrowly in court.
Overly generic “hematopoietic stem cell mobilization” claims tend to create ambiguity unless the patent specifies operational parameters.

Which companies are challenging patents for stem cell mobilization drugs, and what litigation matters?

What litigation posture tends to appear?

ANDA Paragraph IV filings for small molecules generally focus on tight Orange Book listings: compound coverage, method-of-use claims, and formulation claims.
Biosimilar litigation (for G-CSF) can arise around:
- patent listings for manufacturing processes or analytical characterization,
- dosing form and stability claims,
- interchangeability and label scope.

What settlements usually change?

Settlements typically:

define launch dates or market-entry carve-outs,
constrain marketing language (label indications),
impose supply or distribution limits for the generic entrant,
define cross-licenses or covenants not to sue.

What formulation patents protect HSC mobilization drugs, and can generics circumvent them?

What formulation elements can be protected?

Key formulation protection levers include:

excipients and buffers used to stabilize active ingredient,
salt form selection and particle properties,
container-closure configuration,
lyophilized vs liquid presentation,
storage conditions and shelf-life extension strategies.

How do formulation barriers play out?

Even where method-of-use claims are designed around, formulation patents can keep a branded product entrenched if:

generic must adopt a non-infringing formulation approach,
stability and bioequivalence are harder to demonstrate,
court interpretations treat the formulation as essential to claimed performance.

How do biosimilar and generic risks differ for G-CSF versus plerixafor?

What is the biosimilar launch risk for G-CSF mobilization?

G-CSF markets typically support multiple biosimilars.
The competitive risk is primarily pricing pressure and formulary substitution, not complete therapeutic replacement.
Patent coverage for biologics tends to fragment across:
- process patents,
- analytical method patents,
- formulation/stability,
- label-specific uses.

What is the generic risk for plerixafor?

Small-molecule generic entry depends on:
- whether Orange Book method-of-use patents are stayed or invalidated,
- ability to design around combination regimen claims,
- whether formulation patents constrain ANDA acceptability.

How does plerixafor compare with G-CSF-based mobilization on IP and market dynamics?

Market-driven differentiation

Plerixafor is used when predictable mobilization is clinically urgent or when prior mobilization failed.
G-CSF is the default backbone in many protocols, so its competitive landscape is broader and more crowded.

IP-driven differentiation

Plerixafor’s patent estate concentrates on CXCR4 antagonism and specific mobilization contexts, which can limit generic and biosimilar-like substitution.
G-CSF’s IP landscape is more mature and includes multiple entrants; the originator’s incremental leverage often shrinks faster once biosimilars reach scale.

What generic entry risks exist for hematopoietic stem cell mobilization indications?

Where do risks concentrate?

Generic entry risk tends to concentrate on:

Autologous transplant mobilization claims tied to label language.
Poor mobilizer or mobilization-failure prediction subgroups.
Combination regimens with G-CSF where dosing sequence matters.

What triggers a shift from legal to commercial entry?

Even after a generic can legally launch, uptake depends on:

center protocols,
payer prior authorization,
reimbursement differentials for plerixafor vs G-CSF-intensive fallback strategies.

What is the geographic coverage of HSC mobilization patent estates?

How jurisdictional differences change strategy

US: Orange Book-driven litigation and ANDA pathway define early commercial entry.
EU: EP validations and national phase enforcement can delay or redirect challenges.
UK/other: local patent actions and enforcement venues influence timing.

Where would enforcement likely matter most?

Jurisdictions with strong enforcement track records for method-of-use and combination claims.
Regions with active transplant markets that support rapid uptake of branded products.

Key Takeaways

HSC mobilization drug IP clusters into CXCR4 antagonism (notably plerixafor) and regimen-driven cytokine/chemo mobilization (notably G-CSF-based backbones).
Patent strength is highest where method-of-use and G-CSF combination regimen claims map directly to FDA-label indications and operational protocols.
Exclusivity and Orange Book status drive Paragraph IV strategy for small molecules; biosimilar competition drives earlier unit-price pressure for G-CSF.
Litigation and settlements typically determine launch timing more than compound-level expiration alone.
Commercial dynamics are governed by transplant-center protocol adoption and payer authorization, so legal entry does not automatically translate into immediate market share transfer.

FAQs

1) What claims usually block generic plerixafor entry for autologous stem cell mobilization?
Method-of-use and combination regimen patents tied to mobilization in poor mobilizers and coordinated dosing with G-CSF.

2) How do mobilization-failure definitions affect patent scope and litigation?
They narrow claim interpretation to operational patient subsets that align with protocol-based label language.

3) Do biosimilars of G-CSF replace the need for CXCR4 antagonists like plerixafor?
Not universally; CXCR4 antagonists are used for predictable yield needs or failure risk scenarios that biosimilar G-CSF regimens may not fully address.

4) What manufacturing or formulation risks most often slow generic launches for mobilization drugs?
Formulation stability, container-closure design, and bioequivalence alignment with branded performance.

5) When a key method-of-use patent expires, can a competitor launch immediately without payer changes?
Legally yes, commercially often no; utilization management and center protocol adoption commonly lag behind patent expiry.

References (APA)

No sources were cited because no specific drug, NDA/BLA identifiers, Orange Book listings, or patent numbers were provided in the prompt.